(Total Views: 465)
Posted On: 07/06/2021 10:25:17 PM
Post# of 148899
Video today: Once again, my Pourhassan deocoder is not working.
On today's Proactive video, Pourhassan claims, among other things:
1) Dr. Chris Recknor has converted a "14 month delay" into apparently zero delay as to the receptor occupancy portion of the HIV BLA filing
2) Recknor replaced the "Stanford" people in order to fix the problems with receptor occupancy testing at Cytodyn.
Good thing a "14 month delay" was never offered publicly as a solution to the HIV receptor occupancy problem.
Recknor is a clinical physician. I don't think Recknor has any experience with receptor occupancy technical details. How did he manage to fix what Rahman could not?
The Stanford diss seems aimed at Patterson, but who knows. Recknor joined Cytodyn on March 16 roughly eight months after Patterson was kicked out. I guess since Recknor is apparently on a roll might as well give him credit for everything that goes well.
Seems to me that Recknor has no prior experience in anything leronlimab related, yet he is able to solve many substantial problems.
My conclusion is that it doesn't take much to solve Cytodyn's problems, which is what I would expect.
Just get a few competent people and things get better quickly.
Cytodyn has always had Dr. Nitya Ray, who has managed not only to fully qualify the world's largets antibody manufacturer, Samsung, but also to stockpile 1.2 million vials of leronlimab.
So prior to Recknor, Cytodyn had at least one good worker.
Maybe Pourhassan and crew have learned enough in the last year or two to get something done.
I suspect that by the time the votes are counted for the 13D slate of directors all of Cytodyn's current efforts will not have readouts.
Last year, Cytodyn's annual meeting was held on September 30.
I doubt anything will read out before that.
Hard for me to see today's board of directors surviving the vote but I know nothing.
On today's Proactive video, Pourhassan claims, among other things:
1) Dr. Chris Recknor has converted a "14 month delay" into apparently zero delay as to the receptor occupancy portion of the HIV BLA filing
2) Recknor replaced the "Stanford" people in order to fix the problems with receptor occupancy testing at Cytodyn.
Good thing a "14 month delay" was never offered publicly as a solution to the HIV receptor occupancy problem.
Recknor is a clinical physician. I don't think Recknor has any experience with receptor occupancy technical details. How did he manage to fix what Rahman could not?
The Stanford diss seems aimed at Patterson, but who knows. Recknor joined Cytodyn on March 16 roughly eight months after Patterson was kicked out. I guess since Recknor is apparently on a roll might as well give him credit for everything that goes well.
Seems to me that Recknor has no prior experience in anything leronlimab related, yet he is able to solve many substantial problems.
My conclusion is that it doesn't take much to solve Cytodyn's problems, which is what I would expect.
Just get a few competent people and things get better quickly.
Cytodyn has always had Dr. Nitya Ray, who has managed not only to fully qualify the world's largets antibody manufacturer, Samsung, but also to stockpile 1.2 million vials of leronlimab.
So prior to Recknor, Cytodyn had at least one good worker.
Maybe Pourhassan and crew have learned enough in the last year or two to get something done.
I suspect that by the time the votes are counted for the 13D slate of directors all of Cytodyn's current efforts will not have readouts.
Last year, Cytodyn's annual meeting was held on September 30.
I doubt anything will read out before that.
Hard for me to see today's board of directors surviving the vote but I know nothing.
(3)
(5)Scroll down for more posts ▼
